Literature DB >> 33471452

Lower or Higher Oxygenation Targets for Acute Hypoxemic Respiratory Failure.

Olav L Schjørring1, Thomas L Klitgaard1, Anders Perner1, Jørn Wetterslev1, Theis Lange1, Martin Siegemund1, Minna Bäcklund1, Frederik Keus1, Jon H Laake1, Matthew Morgan1, Katrin M Thormar1, Søren A Rosborg1, Jannie Bisgaard1, Annette E S Erntgaard1, Anne-Sofie H Lynnerup1, Rasmus L Pedersen1, Elena Crescioli1, Theis C Gielstrup1, Meike T Behzadi1, Lone M Poulsen1, Stine Estrup1, Jens P Laigaard1, Cheme Andersen1, Camilla B Mortensen1, Björn A Brand1, Jonathan White1, Inge-Lise Jarnvig1, Morten H Møller1, Lars Quist1, Morten H Bestle1, Martin Schønemann-Lund1, Maj K Kamper1, Mathias Hindborg1, Alexa Hollinger1, Caroline E Gebhard1, Núria Zellweger1, Christian S Meyhoff1, Mathias Hjort1, Laura K Bech1, Thorbjørn Grøfte1, Helle Bundgaard1, Lars H M Østergaard1, Maria A Thyø1, Thomas Hildebrandt1, Bülent Uslu1, Christoffer G Sølling1, Nette Møller-Nielsen1, Anne C Brøchner1, Morten Borup1, Marjatta Okkonen1, Willem Dieperink1, Ulf G Pedersen1, Anne S Andreasen1, Lone Buus1, Tayyba N Aslam1, Robert R Winding1, Joerg C Schefold1, Stine B Thorup1, Susanne A Iversen1, Janus Engstrøm1, Maj-Brit N Kjær1, Bodil S Rasmussen1.   

Abstract

BACKGROUND: Patients with acute hypoxemic respiratory failure in the intensive care unit (ICU) are treated with supplemental oxygen, but the benefits and harms of different oxygenation targets are unclear. We hypothesized that using a lower target for partial pressure of arterial oxygen (Pao2) would result in lower mortality than using a higher target.
METHODS: In this multicenter trial, we randomly assigned 2928 adult patients who had recently been admitted to the ICU (≤12 hours before randomization) and who were receiving at least 10 liters of oxygen per minute in an open system or had a fraction of inspired oxygen of at least 0.50 in a closed system to receive oxygen therapy targeting a Pao2 of either 60 mm Hg (lower-oxygenation group) or 90 mm Hg (higher-oxygenation group) for a maximum of 90 days. The primary outcome was death within 90 days.
RESULTS: At 90 days, 618 of 1441 patients (42.9%) in the lower-oxygenation group and 613 of 1447 patients (42.4%) in the higher-oxygenation group had died (adjusted risk ratio, 1.02; 95% confidence interval, 0.94 to 1.11; P = 0.64). At 90 days, there was no significant between-group difference in the percentage of days that patients were alive without life support or in the percentage of days they were alive after hospital discharge. The percentages of patients who had new episodes of shock, myocardial ischemia, ischemic stroke, or intestinal ischemia were similar in the two groups (P = 0.24).
CONCLUSIONS: Among adult patients with acute hypoxemic respiratory failure in the ICU, a lower oxygenation target did not result in lower mortality than a higher target at 90 days. (Funded by the Innovation Fund Denmark and others; HOT-ICU ClinicalTrials.gov number, NCT03174002.).
Copyright © 2021 Massachusetts Medical Society.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33471452     DOI: 10.1056/NEJMoa2032510

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   176.079


  48 in total

1.  A COASTal view: where prior beliefs and uncertainty collide.

Authors:  Mark J Peters; William Macharia; Elizabeth Molyneux
Journal:  Intensive Care Med       Date:  2021-04-27       Impact factor: 17.440

2.  Effect of Low-Normal vs High-Normal Oxygenation Targets on Organ Dysfunction in Critically Ill Patients: A Randomized Clinical Trial.

Authors:  Harry Gelissen; Harm-Jan de Grooth; Yvo Smulders; Evert-Jan Wils; Wouter de Ruijter; Roel Vink; Bob Smit; Jantine Röttgering; Leila Atmowihardjo; Armand Girbes; Paul Elbers; Pieter-Roel Tuinman; Heleen Oudemans-van Straaten; Angelique de Man
Journal:  JAMA       Date:  2021-09-14       Impact factor: 56.272

3.  Oxygen Supplementation and Hyperoxia in Critically Ill Cardiac Patients: From Pathophysiology to Clinical Practice.

Authors:  Alexander Thomas; Sean van Diepen; Rachel Beekman; Shashank S Sinha; Samuel B Brusca; Carlos L Alviar; Jacob Jentzer; Erin A Bohula; Jason N Katz; Andi Shahu; Christopher Barnett; David A Morrow; Emily J Gilmore; Michael A Solomon; P Elliott Miller
Journal:  JACC Adv       Date:  2022-08-26

Review 4.  Year in Review 2021: Noteworthy Literature in Cardiothoracic Anesthesia.

Authors:  Aaron Smoroda; David Douin; Joseph Morabito; Matthew Lyman; Meghan Prin; Bryan Ahlgren; Andrew Young; Elijah Christensen; Benjamin A Abrams; Nathaen Weitzel; Nathan Clendenen
Journal:  Semin Cardiothorac Vasc Anesth       Date:  2022-05-17

5.  Intensivists' response to hyperoxemia in mechanical ventilation patients: The status quo and related factors.

Authors:  Zi-Wei Ke; Yue Jiang; Ya-Ping Bao; Ye-Qin Yang; Xiao-Mei Zong; Min Liu; Xiang-Yun Guan; Zhong-Qiu Lu
Journal:  World J Emerg Med       Date:  2021

6.  Determining a target SpO2 to maintain PaO2 within a physiological range.

Authors:  Jantine G Röttgering; Angelique M E de Man; Thomas C Schuurs; Evert-Jan Wils; Johannes M Daniels; Joost G van den Aardweg; Armand R J Girbes; Yvo M Smulders
Journal:  PLoS One       Date:  2021-05-13       Impact factor: 3.240

Review 7.  Management of Respiratory Failure: Ventilator Management 101 and Noninvasive Ventilation.

Authors:  Steven D Pearson; Jay L Koyner; Bhakti K Patel
Journal:  Clin J Am Soc Nephrol       Date:  2022-03-10       Impact factor: 8.237

Review 8.  Oxygen Toxicity in Critically Ill Adults.

Authors:  Chad H Hochberg; Matthew W Semler; Roy G Brower
Journal:  Am J Respir Crit Care Med       Date:  2021-09-15       Impact factor: 30.528

9. 

Authors:  Edimar Pedrosa Gomes; Maycon Moura Reboredo; Giovani Bernardo Costa; Fabrício Sciammarella Barros; Erich Vidal Carvalho; Bruno Valle Pinheiro
Journal:  Med Intensiva       Date:  2022-05-02       Impact factor: 2.799

10.  Conservative oxygen therapy for critically ill patients: a meta-analysis of randomized controlled trials.

Authors:  Xiao-Li Chen; Bei-Lei Zhang; Chang Meng; Hui-Bin Huang; Bin Du
Journal:  J Intensive Care       Date:  2021-07-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.